menu search

PACB / Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio

Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio
Pacific Biosciences of California "PacBio" is a prime candidate for the "Bio Boom" Portfolio in my Compounding Healthcare Seeking Alpha Marketplace Service. I discuss how PACB meets the criteria. PacBio's HiFi and SMRT sequencing technology continues to fuel growth. The company believes they are on track to hit their full-year revenue guidance of around $160M-$170M. Read More
Posted: Jul 27 2022, 02:40
Author Name: Seeking Alpha
Views: 103151

PACB News  

PacBio (PACB) Tops on Q3 Earnings, Raises FY23 Revenue View

By Zacks Investment Research
October 31, 2023

PacBio (PACB) Tops on Q3 Earnings, Raises FY23 Revenue View

PacBio (PACB) witnesses strong revenue growth in the third quarter, partly aided by customers' continued product transition to the Revio system. more_horizontal

Pacific Biosciences of California, Inc. (PACB) Q3 2023 Earnings Call Transcript

By Seeking Alpha
October 30, 2023

Pacific Biosciences of California, Inc. (PACB) Q3 2023 Earnings Call Transcript

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q3 2023 Earnings Conference Call October 30, 2023 4:30 PM ET Company Participants Todd Friedman more_horizontal

Three Reasons to Add PacBio (PACB) Stock to Your Portfolio

By Zacks Investment Research
October 6, 2023

Three Reasons to Add PacBio (PACB) Stock to Your Portfolio

PacBio's (PACB) product development activities raise optimism about the stock. more_horizontal

Strength Seen in Pacific Biosciences (PACB): Can Its 8.9% Jump Turn into More Strength?

By Zacks Investment Research
September 14, 2023

Strength Seen in Pacific Biosciences (PACB): Can Its 8.9% Jump Turn into More Strength?

Pacific Biosciences (PACB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estima more_horizontal

Pacific Biosciences: Looks Appealing In The Fast-Growing Long-Read Sequencing Market

By Seeking Alpha
September 10, 2023

Pacific Biosciences: Looks Appealing In The Fast-Growing Long-Read Sequencing Market

Pacific Biosciences has a leading position within the fast-growing long-read DNA sequencer market. Moreover, it is expanding its high-accuracy long-re more_horizontal

Here's Why You Should Retain PacBio (PACB) Stock for Now

By Zacks Investment Research
September 5, 2023

Here's Why You Should Retain PacBio (PACB) Stock for Now

PacBio's (PACB) product development activities raise optimism about the stock. more_horizontal

PacBio (PACB) Inks Research Collaboration for Genome Sequencing

By Zacks Investment Research
August 9, 2023

PacBio (PACB) Inks Research Collaboration for Genome Sequencing

PacBio (PACB) and GeneDx sign a deal with the University of Washington to study long-read sequencing in rare diseases. The study will use PacBio's Rev more_horizontal

PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View

By Zacks Investment Research
August 3, 2023

PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View

PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system. more_horizontal


Search within

Pages Search Results: